Accesso Biotech Corporation

What Accesso Biotech Corporation does

Accesso Biotech Corporation is a privately held, Santa Clara, California-based biotechnology company (1–10 employees) developing the proprietary iFIC (immunoFluorescence Imaging Cytometry) platform — a portable imaging cytometry system that performs absolute T/B/NK and CD4/CD8 immunophenotyping from 10–20 µL of whole blood in under 35 minutes without lasers, sheath fluidics, lysis, washing, or counting beads. The platform underpins two commercial products launched in 2025: the VITA CD4 Point-of-Care Test, targeted at advanced HIV disease (AHD) management in low- and middle-income countries where CD4 access is limited, and the iFIC Cytometer, targeted at translational immunology and cell therapy / immunotherapy developers needing benchtop, low-maintenance cell analysis.

The company operates an enterprise-led GTM combining direct sales (quote-based, conference-driven) with an alpha program offering early-access iFIC cytometers to research organizations in exchange for feedback and assay co-development. Marketing relies on peer-reviewed publications (Clinica Chimica Acta, medRxiv), conference presence at IAS, ICASA, INTEREST, AABB, ISCT, and partnerships with academic validation sites (UCSF/SFGH, ITM Antwerp, Wits Diagnostic Innovation Hub). In December 2025 the company secured financial and strategic support from the Gates Foundation, Unitaid, and the Clinton Health Access Initiative (CHAI) to scale VITA CD4 manufacturing and expand LMIC access, co-aligning with the Future of HIV Markets Forum.

Revenue mechanics are split across hardware/instrument sales (VITA system and iFIC cytometer), cartridge/consumable economics implied by the S.I.R. cartridge workflow, and managed-services-style alpha co-development. Pricing is not publicly disclosed and is quote-based, with multi-year contract cadence and LMIC cost-down enabled by funder subsidies. The company is pre-revenue at commercial scale, recently productized, and remains sub-10 in headcount, with material dependence on three global-health funders and a narrow set of institutional validation partners for near-term commercial traction.

Name

Accesso Biotech Corporation

Legal name

Accesso Biotech Corporation

Website

https://accessobio.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Accesso Biotech Corporation is a Santa Clara-based private biotech commercializing its proprietary iFIC imaging cytometry platform through the VITA CD4 point-of-care HIV test for low- and middle-income countries and the iFIC Cytometer for translational immunology and cell therapy research.

Ownership category

akta.pro rank

Product category

Point-of-Care Diagnostic Devices

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)

Keywords

• Point-of-care diagnostics
• Flow cytometry instruments
• HIV CD4 testing
• Immunophenotyping assays
• Cell analysis platforms

Headquarters

HQ city

Santa Clara

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations

Revenue model

1. iFIC Imaging Cytometer Hardware Sales: Sale of portable benchtop iFIC imaging cytometry instruments to research institutions, healthcare facilities, and cell therapy companies for translational immunology and cell analysis applications
2. VITA CD4 Test System: Point-of-care CD4 test system including instruments and cartridges for HIV management in low and middle income countries
3. Alpha Program / Early Access: Co-development partnerships with alpha partners in exchange for feedback and assay development collaboration, potentially leading to commercial adoption

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Core offering

Accesso Biotech Corporation develops and sells portable cell analysis instruments and diagnostic test systems based on its proprietary iFIC (immunoFluorescence Imaging Cytometry) technology platform. Its two main commercial products are the VITA™ point-of-care CD4 test for management of advanced HIV disease in low- and middle-income countries and the iFIC™ Cytometer, a portable benchtop imaging cytometer for translational immunology, cell therapy, and immunotherapy research. Both products deliver absolute T, B, NK, CD4, and CD8 counts from small whole blood samples without lasers, sheath fluidics, lysis, washing, or counting beads.

Product overview

Accesso Biotech Corporation offers a portfolio of cell analysis products powered by the proprietary iFIC™ (immunoFluorescence Imaging Cytometry) technology platform. The main products are the VITA™ CD4 Test (a point-of-care diagnostic for HIV management) and the iFIC™ Cytometer (a portable benchtop system for translational immunology and cell therapy research). Both products enable accessible cell counting and immunophenotyping without traditional flow cytometry requirements like lasers or sheath fluidics.

Differentiator

Problem solved

Functional benefit

Brands

• VITA CD4 Test: Point-of-care CD4 test for management of advanced HIV disease (AHD) in low- and middle-income countries
• iFIC Cytometer

Products and services

• VITA™ CD4 Test Point-of-care CD4 counting test system for managing advanced HIV disease (AHD) in low- and middle-income countries. Provides CD4 cell count results within minutes at the point of care to support immediate treatment decisions, particularly where viral load testing is unavailable. Targeted at public health systems, clinics, and hospitals in LMICs.
• iFIC™ Cytometer Portable benchtop imaging cytometry system for translational immunology, cell therapy development, and immunotherapy research. Provides absolute T, B, NK, CD4, and CD8 counts from 10-20 µL of whole blood in under 35 minutes using the S.I.R. workflow. Targeted at academic research institutions, translational immunology laboratories, and cell and gene therapy companies.

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered major and core.

• Institute of Tropical Medicine, AntwerpmajorStrategic or Co-development Partner · 16 December 2025Academic research partner for analytical performance validation of VITA CD4 test, collaborating with UCSF researchers on clinical studies. Lead author institution on performance evaluation publications.
• University of Witwatersrand / Wits Diagnostic Innovation HubmajorStrategic or Co-development Partner · 31 March 2025South African research partner conducting performance evaluation of VITA Point-of-Care CD4 Test for HIV care using clinical samples. Poster presentation at INTEREST 2026 conference.
• UCSF / San Francisco General HospitalcoreStrategic or Co-development Partner · 16 December 2024Clinical validation partner for iFIC imaging cytometer, conducting head-to-head testing against Beckman Coulter Aquios IVD flow cytometer using HIV+ whole blood samples. Collaborative research published in Clinica Chimica Acta.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Cytek Biosciences: Flow cytometry company focused on immunophenotyping using full-spectrum fluorescence detection (Aurora, Northern Lights) for cell therapy QC and translational immunology — directly comparable to Accesso's iFIC platform in target customer (cell therapy developers, immunology researchers) and core functionality.
• Sysmex Partec: Sysmex-owned manufacturer of point-of-care CD4 counters (CyFlow, autoMACS) historically deployed across African HIV programs. Most direct VITA competitor in LMIC POC CD4 testing workflow, with deeper installed base but older product architecture.

Broad incumbents

• Beckman Coulter Life Sciences: Danaher-owned flow cytometry and clinical diagnostics leader whose Aquios IVD flow cytometer is named as Accesso's head-to-head clinical comparator. Overlapping CD4/immunophenotyping reagent and instrument portfolio in both clinical labs and LMIC HIV markets.
• Bio-Rad Laboratories: Broad life science tools incumbent with the ZE5 and S3e flow cytometers serving translational immunology and cell therapy QC, plus clinical diagnostics reagents. Differentiated by larger installed base and broader reagent menus; Accesso competes on portability and workflow simplicity.
• Becton Dickinson (BD Biosciences / BD FACS): Established flow cytometry incumbent (FACSChorus, FACSCalibur, FACSDiscover) with the BD FACSPresto point-of-care CD4 system directly competing with Accesso's VITA in LMIC HIV diagnostics. Large installed base, full reagent menu, and global distribution.

Emerging players

• Stratedigm: Specialty flow cytometry manufacturer (A1000) focused on benchtop, modular cell analyzers for immunology and cell therapy research. Comparable to iFIC Cytometer in targeting benchtop, accessible cytometers with simplified workflows.
• NanoCellect Biomedical: Developer of microfluidic, cartridge-based cell sorting and analysis (WOLF Cell Sorter) for cell therapy QC and translational genomics. Comparable to iFIC in emphasizing microfluidic/microfluidic-free, cartridge-format cell analysis outside traditional flow cytometer form factors.
• Daktari Diagnostics: Daktari developed the IsoChip and CD4 POC platform for LMIC HIV monitoring — a directly comparable point-of-care CD4 counting product targeting the same sub-Saharan African markets and global health funders. Reflects the niche but contested nature of this category.
• CytoFchip / ChipCytometry (Zellkraftwerk, now Canopy Biosciences): Zellkraftwerk's ChipCytometry platform (now under Canopy Biosciences) performs imaging cytometry on a chip-based, no-fluidics workflow for immunophenotyping, comparable in approach to Accesso's imaging cytometry principle applied to cell analysis without traditional flow cytometer components.
• Apogee Flow Systems: UK-based manufacturer of small-footprint, robust flow cytometers (FlowCyte, MiniFlow) for cell therapy QC and translational immunology. Comparable to iFIC Cytometer in targeting decentralized, lower-complexity cell analysis use cases for cell therapy developers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/VITA_CD4

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Accesso Biotech Corporation